Eradicate Cancer - Can advanced immunotherapy make it possible? The conference title deliberately poses a provocative question and call to action. With unprecedented successes in the clinic immunotherapy is rapidly emerging as the core medical platform for the treatment of cancer. The so-called Chimeric Antigen Receptor T cells (CAR-T) and checkpoint blockade inhibitors, are the pillars to this immuno-oncology revolution.
The conference will embrace the latest technologies and clinical advances, including ‘supercharging’ a patient’s immune system by firstly genetic engineering, empowering T cells with a cancer tracking ’GPS’ creating ‘cancer smart’ killer T cells, and secondly the removal of natural ‘hand brakes’ on immune responses, so they are better able to respond to cancers. These so-called Chimeric Antigen Receptor T cells (CAR-T) and checkpoint blockade inhibitors, respectively, are the pillars to this immuno-oncology revolution. Fundamental to this is the management of treatment related adverse events and the establishment of safe, effective and practical methods for gene editing lymphocytes. It will also evaluate current strategies to rejuvenate and reconstruct the immune system of cancer patients, given the common immunodeficiency they present, as a result of chemotherapy and even natural aging.
Those interested or involved in the field are encouraged to register their interest now using the subscribe button on the right.